Submission of BRSR FY 2025-26

7th August 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E), Mumbai – 400051 Dalal Street, Mumbai- 400 001 Security Symbol: IOLCP Security Code: 524164 Sub.: Submission of Business Responsibility and Sustainability Report for FY 2025-26 Pursuant to Regulation 34 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Business Responsibility and Sustainability Report ("BRSR") of the Company for the financial year 2025-26. The BRSR forms an integral part of the Company's Integrated Annual Report for the financial year 2025-26. The Annual Report containing the BRSR is available on the website of the Company at the following link: https://www.iolcp.com/uploads/Annual_Report_2025-26.pdf Kindly take the above on record. Thanking you. Yours faithfully, for IOL Chemicals and Pharmaceuticals Limited Abhay Raj Singh Sr. Vice President & Company Secretary Business Responsibility & Sustainability Reporting SECTION A: GENERAL DISCLOSURES I. Details of the listed entity 1 Corporate Identity Number (CIN) of the Listed Entity L24116PB1986PLC007030 2 Name of the Listed Entity IOL Chemicals and Pharmaceuticals Limited 3 Year of incorporation 1986 4 Registered office address Village Fatehgarh Channa, Mansa Road, District Barnala-148101, Punjab, India 5 Corporate address 85, Industrial Area 'A' Ludhiana - 141003, Punjab, India. 6 E-mail investor@iolcp.com 7 Telephone +(91)-(0161)-4560500 8 Website www.iolcp.com 9 Financial year for which reporting is being done 2025-26 10 Name of the Stock Exchange(s) where 1. The National Stock Exchange of India Limited (NSE) shares are listed 2. BSE Limited (BSE) 11 Paid-up Capital Rs 58,70,55,020 12 Name and contact details (telephone, email Mr Abhay Raj Singh address) of the person who may be contacted in +(91)-(0161)-4560500 case of any queries on the BRSR report abhayrajsingh@iolcp.com 13 Reporting boundary - Are the disclosures under Standalone basis this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together). 14 Name of assurance provider Intertek India Private Limited 15 Type of assurance obtained Reasonable Assurance II. Products/services 16. Details of business activities (accounting for 90% of the turnover): S. No. Description of Main Activity Description of Business Activity % of Turnover of the entity 1. Manufacturing Pharma Segment 60% 2. Manufacturing Chemical Segment 40% 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): S. No. Product/Service NIC Code % of total Turnover contributed 1 Active Pharma Ingredients 21001 59.66% and Intermediates 2 Specialty Chemicals 20119 39.43% 3 Other 20119 / 21001 0.91% III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National 1 3 4 International - - - 19. Markets served by the entity: a. Number of locations Locations Number National (No. of States) 23 International (No. of Countries) 70 IOL CHEMICALS AND PHARMACEUTICALS LIMITED Corporate Overview Statutory Reports Financial Statements Integrated Annual Report 2025-26 b. What is the contribution of exports as a percentage of the total turnover of the entity? c. A brief on types of customers 1. Specialty Chemicals/Products Manufacturing Companies 2. Pharmaceuticals Finished Dosage Manufacturing Companies IV. Employees 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled): S. Total Male Female Particulars No. (A) No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1 Permanent (D) 3095 2995 96.77% 100 3.23% 2 Other than Permanent (E) 497 467 93.96% 30 6.04% 3 Total employees (D + E) 3592 3462 96.38% % 130 3.62% WORKERS 4 Permanent (F) 5 Other than Permanent (G) NIL 6 Total workers (F + G) b. Differently abled Employees and workers: S. Total Male Female Particulars No. (A) No. (B) % (B / A) No. (C) % (C / A) DIFFERENTLY ABLED EMPLOYEES 1 Permanent (D) 2 Other than Permanent (E) 3 Total differently abled employees (D + E) DIFFERENTLY ABLED WORKERS 4 Permanent (F) 5 Other than Permanent (G) 6 Total differently abled workers (F + G) 21. Participation/Inclusion/Representation of women Total No. and percentage of Females (A) No. (B) % (B / A) Board of Directors 8 1 12.5% Key Management Personnel 2 0 0.00% 22. Turnover rate for permanent employees and workers FY 2025-2026 FY 2024-2025 FY 2023-24 (Turnover rate (Turnover (Turnover rate in the year prior to the rate in current FY) in previous FY) previous FY) Male Female Total Male Female Total Male Female Total Permanent Employees 16.00% 19.10% 16.10% 14.90% 15.80% 14.90% 19.00% 33.80% 19..4% Permanent Workers 0 0 0 0 0 0 0 0 0 Business Responsibility & Sustainability Reporting (Contd..) V. Holding, Subsidiary and Associate Companies (including joint ventures) 23. Names of holding / subsidiary / associate companies / joint ventures % of Name of the holding / Indicate whether Does the entity indicated at shares S. subsidiary / associate holding/ column A, participate in the held by No. companies / Subsidiary/ Associate/ Business Responsibility initiatives listed joint ventures (A) Joint Venture of the listed entity? (Yes/No) entity 1 IOL- Foundation Wholly owned Subsidiary 100% No 2 IOL Specialty Chemicals Limited Wholly owned Subsidiary 100% No 3 IOL Pharmaxis UK Limited Wholly owned Subsidiary 100% No VI. CSR Details 24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No): Yes (ii) Turnover (in H) 2319.06 Crore (iii) Net worth (in H) 1798.38 Crore VII. Transparency and Disclosures Compliances 25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct: Grievance Redressal FY 2025-26 FY 2024-25 Mechanism Current Financial Year Previous Financial Year Stakeholder in Place (Yes/No) group from whom Number of Number of (If Yes, then Number of Number of complaint is received complaints complaints provide web-link complaints complaints pending Remarks pending Remarks for grievance filed during filed during resolution at resolution at redress policy) the year the year close of the year close of the year Communities Yes Nil Nil Nil Nil Investors (other https://www. Nil Nil Nil Nil than shareholders) iolcp.com/ investors/services Shareholders Yes 2 Nil 5 Nil https://www. iolcp.com/ investors/services Employees and workers Nil Nil Nil Nil Customers Yes Nil Nil Nil Nil Value Chain Partners https://www. Nil Nil Nil Nil iolcp.com/ about-us/policies Other (please specify) Nil Nil Nil Nil 26. Overview of the entity’s material responsible business conduct issues Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with its financial implications, as per the following format As a pharmaceuticals and Specialty chemical firm, we have identified, evaluated and reported on certain key issues. In FY 2025-26, we completed a materiality evaluation based on peer review across environmental, social and governance dimensions as per GRI Requirement. The evaluation process has provided us with great insights into topics that are important to us our operations, as well as how they might impact our future. IOL CHEMICALS AND PHARMACEUTICALS LIMITED Corporate Overview Statutory Reports Financial Statements Integrated Annual Report 2025-26 Indicate Financial whether Rationale for In case of risk, implications of the S. Material risk or identifying the appr [Showing first 8,000 characters — download PDF for full document]